Zoetis Inc. (NYSE:ZTS) Shares Sold by Park National Corp OH

Park National Corp OH lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 3.4% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 89,335 shares of the company’s stock after selling 3,178 shares during the quarter. Park National Corp OH’s holdings in Zoetis were worth $15,116,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC increased its holdings in Zoetis by 1.2% during the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after purchasing an additional 52 shares during the period. Forum Financial Management LP increased its holdings in Zoetis by 0.8% during the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after purchasing an additional 56 shares during the period. Angeles Wealth Management LLC increased its holdings in Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after purchasing an additional 56 shares during the period. Prossimo Advisors LLC increased its holdings in Zoetis by 1.7% during the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares during the period. Finally, River Street Advisors LLC increased its holdings in Zoetis by 3.4% during the 4th quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after purchasing an additional 58 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock traded down $1.68 during midday trading on Tuesday, reaching $169.22. 1,169,080 shares of the company were exchanged, compared to its average volume of 2,944,101. The company has a market capitalization of $77.22 billion, a price-to-earnings ratio of 32.84, a P/E/G ratio of 2.65 and a beta of 0.89. The firm’s 50-day simple moving average is $165.85 and its 200-day simple moving average is $179.50. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.31 EPS. On average, analysts anticipate that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.02%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. The Goldman Sachs Group reduced their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Stifel Nicolaus reduced their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, HSBC cut their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $211.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.